Tadeusz Dereziński

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.7K citations · Full text

Diabetes Management, Cardiovascular Disease, Diabetes +6

A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes

Kjeld Hermansen, Melanie J. Davies, Tadeusz Dereziński et al. · Diabetes Care · 2006 · 629 citations · Full text

Kidney length normative values in children aged 0–19 years — a multicenter study

Łukasz Obrycki, Jędrzej Sarnecki, Marianna Lichosik et al. · Pediatric Nephrology · 2021 · 64 citations · Full text

Reduced Weight Gain with Insulin Detemir Compared to NPH Insulin Is Not Explained by a Reduction in Hypoglycemia

Melanie J. Davies, Tadeusz Dereziński, Claus Bang Pedersen et al. · Diabetes Technology & Therapeutics · 2008 · 47 citations

Risk factors for cancer development in type 2 diabetes: A retrospective case-control study

Mariusz Dąbrowski, Elektra Szymańska‐Garbacz, Zofia Miszczyszyn et al. · BMC Cancer · 2016 · 45 citations · Full text